Fulvestrant, sold under the brand name Faslodex among others, is a medication used to treat hormone receptor -positive metastatic breast cancer in postmenopausal women with disease progression as well as HR-positive, HER2-negative advanced breast cancer in combination with palbociclib in women with disease progression after endocrine therapy.
| FactSnippet No. 1,660,560 |
Fulvestrant is a selective estrogen receptor degrader and was first-in-class to be approved.
| FactSnippet No. 1,660,561 |
Fulvestrant is used for the treatment of hormone receptor positive metastatic breast cancer or locally advanced unresectable disease in postmenopausal women; it is given by injection.
| FactSnippet No. 1,660,563 |
Fulvestrant has been used in the treatment of peripheral precocious puberty in girls with McCune–Albright syndrome.
| FactSnippet No. 1,660,564 |
Fulvestrant is provided in a castor oil solution containing alcohol, benzyl alcohol, and benzyl benzoate.
| FactSnippet No. 1,660,565 |
Fulvestrant is an antiestrogen which acts as an antagonist of the estrogen receptor and additionally as a selective estrogen receptor degrader.
| FactSnippet No. 1,660,566 |
Fulvestrant, known as 7a-[9-[sulfinyl]nonyl]estradiol, is a synthetic estrane steroid and a derivative of estradiol.
| FactSnippet No. 1,660,567 |
Fulvestrant was the first selective estrogen receptor degrader to be approved.
| FactSnippet No. 1,660,568 |
Fulvestrant was studied in endometrial cancer but results were not promising and as of 2016 development for this use was abandoned.
| FactSnippet No. 1,660,569 |
Fulvestrant cannot be given orally, efforts have been made to develop SERD drugs that can be taken by mouth, including brilanestrant and elacestrant.
| FactSnippet No. 1,660,570 |